Search results
Results from the WOW.Com Content Network
The Quality of Life in Depression Scale (QLDS) assesses the impact that depression has on a patient's quality of life. [44] It was developed by Galen Research in 1992 and was funded by Lilly Industries. [45] Studies utilizing the QLDS include investigations into venlafaxine, [46] duloxetine [47] [48] [49] and bupropion. [50] Diabetes.
The Patient-Reported Outcomes Measurement Information System [1] (PROMIS) provides clinicians and researchers access to reliable, valid, and flexible measures of health status that assess physical, mental, and social well–being from the patient perspective.
The Quality of Life In Depression Scale (QLDS), originally proposed by Sonja Hunt and Stephen McKenna, is a disease specific patient-reported outcome which assesses the impact that depression has on a patient's quality of life. [1] It is the most commonly used measure of quality of life in clinical trials and studies of depression. [2]
EQ-5D is a standardised measure of health-related quality of life developed by the EuroQol Group to provide a simple, generic questionnaire for use in clinical and economic appraisal and population health surveys. EQ-5D assesses health status in terms of five dimensions of health and is considered a ‘generic’ questionnaire because these ...
The scale emerged from synthesis of existing theories including: (a) subjective well-being, (b) developmental life-stages, (c) different categories of human needs, (d) quality of life, and (e) subjective evaluation processes. The scale consists of three axes: Subjective well-being, positive and negative affect, and fulfillment of needs. See a ...
The Quality of Well-Being Scale (QWB) is a general health quality of life questionnaire which measures overall status and well-being over the previous three days in four areas: physical activities, social activities, mobility, and symptom/problem complexes. [1] It consists of 71 items and takes 20 minutes to complete. [2]
It has been used in research studies worldwide in order to determine the effect a given disease has on a patient’s quality of life. Examples of such studies are investigations into the effect of insomnia on brain tumour patients, [ 13 ] fatigue in post-polio patients [ 14 ] and the sleep, fragility and cognition of the elderly.
The earlier palliative group not only had better quality of life based on the Functional assessment of Cancer Therapy-Lung scale and the Hospital Anxiety and Depression Scale, but the palliative care group also had less depressive symptoms (16% vs. 38%, P=0.01) despite having received less aggressive end-of-life care (33% vs. 54%, P=0.05) and ...